The cannabinoid CB

Analgesics / therapeutic use Analgesics, Opioid / pharmacology Animals Cannabinoid Receptor Agonists / pharmacology Conditioning, Operant / drug effects Dose-Response Relationship, Drug Hyperalgesia / drug therapy Male Mice Mice, Inbred C57BL Mice, Knockout Morphine / pharmacology Morphine Dependence / prevention & control Neuralgia / chemically induced Nociception / drug effects Paclitaxel Purines / pharmacology Pyrans / pharmacology Receptor, Cannabinoid, CB2 / agonists Reward Substance Withdrawal Syndrome / drug therapy
CB(2) Morphine Physical dependence Reward Withdrawal

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Nov 2020
Historique:
received: 29 05 2020
revised: 02 09 2020
accepted: 03 09 2020
pubmed: 9 9 2020
medline: 15 5 2021
entrez: 8 9 2020
Statut: ppublish

Résumé

The opioid crisis has underscored the urgent need to identify safe and effective therapeutic strategies to overcome opioid-induced liabilities. We recently reported that LY2828360, a slowly signaling G protein-biased cannabinoid CB

Identifiants

DOI: 10.1016/j.ejphar.2020.173544 PMID: 32896549 PMC: PMC7694697
pubmed: 32896549
pii: S0014-2999(20)30636-1
doi: 10.1016/j.ejphar.2020.173544
pmc: PMC7694697
mid: NIHMS1631242
pii:
doi:

Substances chimiques

Analgesics 0
Analgesics, Opioid 0
CB2 receptor agonist LY2828360 0
Cannabinoid Receptor Agonists 0
Purines 0
Pyrans 0
Receptor, Cannabinoid, CB2 0
Morphine 76I7G6D29C
Paclitaxel P88XT4IS4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173544

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA041229
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA047858
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA042584
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA200417
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA024628
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

Nat Med. 2017 Mar;23(3):355-360
pubmed: 28134928
Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:81-93
pubmed: 18924447
Int J Neuropsychopharmacol. 2017 Mar 1;20(3):269-278
pubmed: 27994006
Br J Pharmacol. 2011 Oct;164(4):1322-34
pubmed: 21434879
BMJ. 2016 Jan 06;352:i20
pubmed: 26739664
J Med Chem. 2013 Jul 25;56(14):5722-33
pubmed: 23795771
Prev Med. 2015 Nov;80:5-9
pubmed: 25871819
J Pharmacol Exp Ther. 2006 Oct;319(1):1-7
pubmed: 16670349
Biol Psychiatry. 2015 Mar 1;77(5):475-87
pubmed: 24853387
Acta Physiol (Oxf). 2012 May;205(1):41-60
pubmed: 22463610
Exp Neurol. 2011 Dec;232(2):154-61
pubmed: 21907196
Curr Opin Pharmacol. 2010 Feb;10(1):80-6
pubmed: 19857996
Neuropsychopharmacology. 2020 Oct;45(11):1781-1792
pubmed: 32079024
Eur J Neurosci. 2005 Jul;22(2):371-9
pubmed: 16045490
Mol Pharmacol. 2019 Feb;95(2):155-168
pubmed: 30504240
Anesth Analg. 2011 Oct;113(4):947-50
pubmed: 21737705
J Pharmacol Exp Ther. 2011 Oct;339(1):173-85
pubmed: 21719468
J Pharmacol Exp Ther. 2018 Jul;366(1):169-183
pubmed: 29540562
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):E5007-15
pubmed: 25368177
Neuropsychopharmacology. 2013 Nov;38(12):2515-24
pubmed: 23817165
Addict Biol. 2017 May;22(3):752-765
pubmed: 26833913
Neuropharmacology. 2011 Feb-Mar;60(2-3):244-51
pubmed: 20849866
Brain Res. 1985 Mar 11;329(1-2):131-42
pubmed: 4038893
J Physiol Sci. 2015 Sep;65(5):407-15
pubmed: 25894754
Neuroscience. 2003;119(3):747-57
pubmed: 12809695
Biol Psychiatry. 2018 Nov 15;84(10):722-733
pubmed: 28823711
Nature. 2000 Dec 7;408(6813):720-3
pubmed: 11130073
J Pharmacol Exp Ther. 2004 Feb;308(2):446-53
pubmed: 14610224
Pain. 2011 Sep;152(9):1976-87
pubmed: 21550725
Toxicol Appl Pharmacol. 1997 Feb;142(2):278-87
pubmed: 9070350
Eur J Neurosci. 2003 Jun;17(12):2750-4
pubmed: 12823482
Eur J Biochem. 1995 Aug 15;232(1):54-61
pubmed: 7556170
Psychopharmacologia. 1976 Mar 16;46(2):141-7
pubmed: 986052
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14228-33
pubmed: 10588688
Front Mol Neurosci. 2020 Apr 28;13:54
pubmed: 32410959
Brain Behav Immun. 2011 Aug;25(6):1223-32
pubmed: 21447380
Br J Pharmacol. 2008 Jan;153(2):319-34
pubmed: 17994113
Exp Neurol. 2006 Oct;201(2):507-14
pubmed: 16797537
J Pharmacol Exp Ther. 2016 Nov;359(2):310-318
pubmed: 27608657
Prog Neurobiol. 2001 Apr;63(5):569-611
pubmed: 11164622
J Neurophysiol. 2004 Dec;92(6):3562-74
pubmed: 15317842
Br J Pharmacol. 2008 Jan;153(2):263-70
pubmed: 17906675
Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):618-27
pubmed: 16862602
Anesth Analg. 2016 Apr;122(4):1031-7
pubmed: 26720619
Addict Biol. 2015 Jan;20(1):43-55
pubmed: 23855434
Nat Neurosci. 2011 Jul 24;14(9):1160-6
pubmed: 21785434
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
J Neuroinflammation. 2005 Dec 12;2:29
pubmed: 16343349
J Neurochem. 2005 Oct;95(2):437-45
pubmed: 16086683
Br J Pharmacol. 2012 Aug;166(8):2371-85
pubmed: 22428664
Neuroscience. 2014 Mar 7;261:23-42
pubmed: 24365460
Eur J Pharmacol. 1996 Apr 11;300(3):227-36
pubmed: 8739213
Mayo Clin Proc. 2015 Jul;90(7):957-68
pubmed: 26141334
J Pain Symptom Manage. 2002 Jul;24(1):71-90
pubmed: 12183097
Eur J Neurosci. 2006 Mar;23(6):1530-8
pubmed: 16553616
Neuropsychopharmacology. 2012 Jun;37(7):1749-63
pubmed: 22414816
Br J Pharmacol. 2007 Jan;150(2):153-63
pubmed: 17160008
Anesthesiology. 2007 Apr;106(4):787-94
pubmed: 17413917
Am J Surg. 2001 Nov;182(5A Suppl):11S-18S
pubmed: 11755892
J Pharmacol Exp Ther. 2018 Dec;367(3):551-563
pubmed: 30275151
Psychopharmacology (Berl). 2013 Oct;229(4):591-601
pubmed: 23652588
Nat Rev Drug Discov. 2008 Dec;7(12):961-2
pubmed: 19043439
Neuroscience. 2007 May 25;146(3):1275-88
pubmed: 17395382
Pharmacol Biochem Behav. 2014 Sep;124:260-8
pubmed: 24999220
Life Sci. 1987 Nov 9;41(19):2229-34
pubmed: 2823042
Mol Pharmacol. 2018 Feb;93(2):49-62
pubmed: 29192123
Trends Neurosci. 1992 May;15(5):186-91
pubmed: 1377426
Methods Enzymol. 2017;593:23-42
pubmed: 28750805
J Pharmacol Exp Ther. 2001 Sep;298(3):1007-14
pubmed: 11504797
Pain Med. 2009 Jan;10(1):35-42
pubmed: 18721170
J Pharmacol Exp Ther. 2017 Aug;362(2):296-305
pubmed: 28592614
Neuroscience. 2005;135(1):235-45
pubmed: 16084654
J Neuroimmunol. 2012 Mar;244(1-2):23-31
pubmed: 22285397
Neuropharmacology. 2017 Apr;116:59-70
pubmed: 28007501
J Stud Alcohol Drugs. 2015 May;76(3):406-13
pubmed: 25978826
Eur J Pharmacol. 2008 Mar 31;583(1):56-61
pubmed: 18279850
Pain. 2001 Dec;94(3):293-304
pubmed: 11731066
Pain. 1983 Jun;16(2):109-10
pubmed: 6877845
Neuron. 2011 Feb 24;69(4):591-4
pubmed: 21338871

Auteurs

Vishakh Iyer (V)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Richard A Slivicki (RA)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Ana C Thomaz (AC)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Genome, Cellular and Developmental Biology Program, Indiana University, Bloomington, IN, USA.

Jonathon D Crystal (JD)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Ken Mackie (K)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Genome, Cellular and Developmental Biology Program, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.

Andrea G Hohmann (AG)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Genome, Cellular and Developmental Biology Program, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA. Electronic address: hohmanna@indiana.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Analgésiques › The cannabinoid CB
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Stupéfiants › Analgésiques morphiniques › The cannabinoid CB
questionsmedicales.fr › Eucaryotes › Animaux › The cannabinoid CB
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Modulateurs des récepteurs de cannabinoïdes › Agonistes des récepteurs de cannabinoïdes › The cannabinoid CB
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Conditionnement (psychologie) › Conditionnement opérant › The cannabinoid CB
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › The cannabinoid CB
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Troubles sensitifs › Troubles somatosensoriels › Hyperalgésie › The cannabinoid CB
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The cannabinoid CB
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › The cannabinoid CB
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › The cannabinoid CB
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Morphinanes › Dérivés de la morphine › Morphine › The cannabinoid CB
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Troubles liés à l'usage de substances psychotropes › Troubles liés aux opiacés › Dépendance à la morphine › The cannabinoid CB
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Névralgie › The cannabinoid CB
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Perception › Perception de la douleur › Nociception › The cannabinoid CB
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Paclitaxel › The cannabinoid CB
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › The cannabinoid CB
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrannes › The cannabinoid CB
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB2 › The cannabinoid CB
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Renforcement (psychologie) › Récompense › The cannabinoid CB
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Syndrome de sevrage › The cannabinoid CB